-
公开(公告)号:US12091602B2
公开(公告)日:2024-09-17
申请号:US17504307
申请日:2021-10-18
发明人: Brent Shanks , George A. Kraus , William Bradley , Jiajie Huo , Kyle Podolak
IPC分类号: C09K15/30 , C07D213/70 , C07D233/84 , C07D235/28 , C07D249/12 , C07D277/36 , C07D285/125 , C07D405/12 , C07D409/12 , C07D417/12 , C09D5/08
CPC分类号: C09K15/30 , C07D213/70 , C07D233/84 , C07D235/28 , C07D249/12 , C07D277/36 , C07D285/125 , C07D405/12 , C07D409/12 , C07D417/12 , C09D5/086
摘要: A heteroaryl-thio-substituted pyrone compound that is a heteroaryl-thio-substituted pyrone or a heteroaryl-thio-substituted coumarin. In various embodiments, the heteroaryl-thio-substituted pyrone compound or a reaction product thereof is a metal corrosion inhibitor.
-
公开(公告)号:US11884680B2
公开(公告)日:2024-01-30
申请号:US17139963
申请日:2020-12-31
发明人: Amogh Boloor
IPC分类号: C07D498/04 , C07D217/24 , C07D413/04 , C07D401/04 , C07D471/04 , C07D405/04 , C07D487/04 , C07D211/94 , C07D401/14 , C07D213/64 , C07D213/73 , C07D213/74 , C07D237/14 , C07D239/54 , C07D239/56 , C07D241/20 , C07D403/04 , C07D405/12 , C07D409/04 , C07D413/06 , C07D417/14 , C07D491/048 , C07D495/04 , C07D213/69 , C07D213/70 , C07D401/12 , C07D405/06
CPC分类号: C07D498/04 , C07D211/94 , C07D213/64 , C07D213/69 , C07D213/70 , C07D213/73 , C07D213/74 , C07D217/24 , C07D237/14 , C07D239/54 , C07D239/56 , C07D241/20 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/04 , C07D413/04 , C07D413/06 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048 , C07D495/04
摘要: The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.
-
公开(公告)号:US11851408B2
公开(公告)日:2023-12-26
申请号:US18221902
申请日:2023-07-14
申请人: NANKAI UNIVERSITY
发明人: Xiaochen Wang , Xinyue Zhou
IPC分类号: C07D213/70 , B01J31/14
CPC分类号: C07D213/70 , B01J31/146
摘要: A method for preparing a pyridine compound substituted with trifluoromethylthio, difluoromethylthio or trifluoromethyl in the meta position is provided, which includes S1. in a glove box filled with nitrogen, adding a catalyst, a solvent, pinacolborane, and pyridine to a reaction flask, stirring the mixture, and performing a reaction at 40-100° C. for 2-12 hours to obtain dihydropyridine; S2. adding a trifluoromethylthio reagent, a difluoromethylthio reagent, or a trifluoromethyl reagent to the reaction flask, stirring the mixture, and performing a reaction at room temperature to 80° C. for 2-12 hours to obtain trifluoromethylthio-, difluoromethylthio- or trifluoromethyl-substituted dihydropyridine; and S3. placing the reaction flask in the air or adding 2,3-dichloro-5,6-dicyanobenzoquinone, stirring same, and performing a reaction at room temperature for 4-12 hours, followed by distillation under reduced pressure to remove the solvent and column chromatography separation to obtain the meta-substituted pyridine compound.
-
公开(公告)号:US20230339860A1
公开(公告)日:2023-10-26
申请号:US18183281
申请日:2023-03-14
申请人: Southern Research Institute , UAB Research Foundation , The United States Government as Represented by the Department of Veterans Affairs
发明人: Mark J. Suto , Bini Mathew , Anupam Agarwal , Amie M. Traylor
IPC分类号: C07C321/28 , C07D217/22 , C07D215/36 , C07D215/48 , C07D213/70 , C07D215/40
CPC分类号: C07D215/36 , C07C321/28 , C07D213/70 , C07D215/40 , C07D215/48 , C07D217/22
摘要: The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
-
公开(公告)号:US20190185431A1
公开(公告)日:2019-06-20
申请号:US16190925
申请日:2018-11-14
发明人: Samedy Ouk , Esmir Gunic , Jean-Michel Vernier , Chixu Chen
IPC分类号: C07D213/70 , A61K31/519 , C07D239/38 , C07D403/10 , C07D405/10 , A61K31/426 , A61K31/4418 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/4725 , A61K31/4965 , A61K31/497 , A61K31/502 , A61K31/505 , A61K31/506 , C07D417/10 , A61K45/06 , C07D417/04 , C07D405/04 , C07D403/04 , C07D401/04 , C07D241/18 , C07D401/10
CPC分类号: C07D213/70 , A61K31/426 , A61K31/4418 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/4725 , A61K31/4965 , A61K31/497 , A61K31/502 , A61K31/505 , A61K31/506 , A61K31/519 , A61K45/06 , C07D239/38 , C07D241/18 , C07D401/04 , C07D401/10 , C07D403/04 , C07D403/10 , C07D405/04 , C07D405/10 , C07D417/04 , C07D417/10
摘要: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
-
公开(公告)号:US20180310559A1
公开(公告)日:2018-11-01
申请号:US15547112
申请日:2016-01-29
IPC分类号: A01N43/40 , C07D213/71
CPC分类号: A01N43/40 , A01N25/04 , A01N47/02 , A61K31/44 , C07D213/70 , C07D213/71
摘要: A bipyridine compound having an excellent controlling effect against noxious arthropods is provided. In particular, a bipyridine compound of formula (I) or an N-oxide thereof is provided in which the variable groups are as described in the specification. Also provided are compositions containing the biypridine compound or an N-oxide thereof, and methods of using such compounds and compositions to control noxious arthropods.
-
7.
公开(公告)号:US10047050B2
公开(公告)日:2018-08-14
申请号:US14355480
申请日:2012-11-02
发明人: Li-Tain Yeh , Barry D. Quart
IPC分类号: C07D213/70 , A61K31/44 , A61K45/06 , A61K31/426 , A61K31/519 , A61K31/4418
CPC分类号: C07D213/70 , A61K31/426 , A61K31/44 , A61K31/4418 , A61K31/519 , A61K45/06 , A61K2300/00
摘要: 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid is useful in the modulation of blood or serum uric acid levels. In some embodiments, 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid is used in the treatment or prevention of disorders related to aberrant levels of uric acid. In some embodiments, 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid is used for reducing serum uric acid levels in a human. Also described herein are compositions comprising 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, and their use in the modulation of blood or serum uric acid levels.
-
公开(公告)号:US09957285B2
公开(公告)日:2018-05-01
申请号:US14906908
申请日:2014-07-01
申请人: SHOWA DENKO K.K.
IPC分类号: B01D53/02 , B01D53/22 , B01D69/14 , C07F3/06 , B01J20/22 , B01J20/28 , C07C7/12 , C07C201/12 , C07D213/06 , C07D213/68 , C07D213/70 , B01J20/34 , B01D53/04 , B01D53/047
CPC分类号: C07F3/06 , B01D53/02 , B01D53/0462 , B01D53/047 , B01D53/228 , B01D69/14 , B01D2253/112 , B01D2253/20 , B01D2256/24 , B01D2257/7022 , B01D2325/12 , B01J20/226 , B01J20/28035 , B01J20/3483 , C07C7/12 , C07C201/12 , C07D213/06 , C07D213/68 , C07D213/70 , Y02C10/08 , C07C11/167 , C07C205/57
摘要: A separating material superior to conventional separating materials, and a separation method are provided, with which 1,3-butadiene is selectively separated and recovered from a mixed gas including 1,3-butadiene and C4 hydrocarbons other than 1,3-butadiene. A metal complex, which comprises a dicarboxylic acid compound (I) (see (I) below) represented by general formula (I), an ion of a metal such as beryllium, and a dipyridyl compound (II) represented by general formula (II), namely L-Z-L (II) (see L below), is characterized by including, as the dipyridyl compound (II), at least two different dipyridyl compounds (II). The metal complex is used as a 1,3-butadiene separating material. Formula (I) L is represented by any of the compounds below.
-
公开(公告)号:US09890148B2
公开(公告)日:2018-02-13
申请号:US14551438
申请日:2014-11-24
申请人: ChemoCentryx, Inc.
发明人: Solomon Ungashe , John J. Wright , Andrew Pennell , Zheng Wei , Anita Melikian
IPC分类号: C07D417/12 , C07D213/26 , C07D213/50 , C07D213/52 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D405/12 , C07D413/12 , A61K31/4409 , A61K31/443 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D239/26 , C07D401/12 , C07D409/12
CPC分类号: C07D417/12 , A61K31/4409 , A61K31/443 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D213/26 , C07D213/50 , C07D213/52 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D239/26 , C07D241/12 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
-
公开(公告)号:US09790183B2
公开(公告)日:2017-10-17
申请号:US15015586
申请日:2016-02-04
申请人: GENENTECH, INC. , CURIS, INC.
发明人: Janet L. Gunzner-Toste , Daniel Sutherlin , Mark S. Stanley , Liang Bao , Georgette M. Castanedo , Rebecca L. Lalonde , Shumei Wang , Mark E. Reynolds , Scott J. Savage , Kimberly Malesky , Michael S. Dina , Michael F. T. Koehler
IPC分类号: C07D213/16 , C07D401/12 , A61K31/44 , C07D213/38 , C07D213/40 , C07D213/56 , C07D213/70 , C07D213/75 , C07D213/81 , C07D213/82 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07F9/58
CPC分类号: C07D213/16 , C07D213/38 , C07D213/40 , C07D213/56 , C07D213/70 , C07D213/75 , C07D213/81 , C07D213/82 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07F9/58
摘要: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
-
-
-
-
-
-
-
-
-